PORTLAND, Ore., Oct. 9 /PRNewswire-FirstCall/ -- Studies presented at
the Modern Vaccine Adjuvants et Delivery Systems Conference and at the AIDS
Vaccine Conference 2006 show improved immunogenicity of vaccines when used
with the Biojector(R) 2000 ("B2000") in cancer and AIDS vaccines.
In a study presented at the Modern Vaccine Adjuvants et Delivery
Systems Conference held September 2006 at the Royal Society of Medicine in
London, the Biojector(R) 2000 showed improved immunogenicity for a cancer
vaccine being developed at Memorial Sloan-Kettering Cancer Center. Dr.
Miguel Perales from Memorial Sloan-Kettering presented data showing
improved immunogenicity when using the B2000 with a cancer vaccine for
melanoma. The presentation, titled "DNA immunization against tumor antigens
using the B2000, a needle free injection device, in pre-clinical mouse
model," showed how the B2000 improved expression, thus making the vaccine
more effective. "Injection of GM-CSF DNA with the B2000 induces measurable
levels of GM-CSF protein in the skin, which are higher than those after
injection with a needle and syringe," stated Dr. Perales. "Using the B2000
to administer melanoma DNA vaccines in mouse models, we were able to show
tumor-specific immune responses as well as tumor protection. In addition to
our positive results in clinical studies of companion animals, these
results support the use of needle-free injection devices, such as the
B2000, for DNA immunization in human clinical trials," said Dr. Perales.
The B2000 is currently being used in human clinical trials for the melanoma
vaccines as well as other vaccines being developed by Memorial
Sloan-Kettering.
In another study presented by the Karolinska Institute of Sweden at the
AIDS Vaccine 2006 International Conference held in Amsterdam in August
2006, the use of the B2000 showed promise in an initial HIV vaccine
clinical study. The study included intramuscular and intradermal injections
in 40 patients. "Initial study results look promising and we are pleased
with the B2000 as a delivery method for our vaccine," commented Dr. Eric
Sandstrom of the Karolinska Institute.
"We are pleased with the usage of our device and technology for the
development of cancer and AIDS vaccines, as well as other vaccines being
used throughout the world," said Jim O'Shea, Chairman, President and CEO of
Bioject. "If we can improve the efficacy of these vaccines and provide an
alternative delivery system to a needle and syringe, we will improve health
care for everyone. We look forward to more exciting results as these
vaccines move forward into further clinical trials."
About Bioject
Bioject Medical Technologies Inc., based in Portland, Oregon, is an
innovative developer and manufacturer of needle-free drug delivery systems.
Needle-free injection works by forcing medication at high speed through a
tiny orifice held against the skin. This creates a fine stream of
high-pressure fluid penetrating the skin and depositing medication in the
tissue beneath. The Company is focused on developing mutually beneficial
agreements with leading pharmaceutical, biotechnology, and veterinary
companies.
This press release contains a forward-looking statement within the
meaning of the Private Securities Litigation Reform Act of 1995, including
statements regarding the Company's ability to continue the advances in
vaccine delivery and future revenues that may be received. Such
forward-looking statement involves known and unknown risks, uncertainties
and other factors that may cause the actual results may be materially
different from any future results expressed or implied by such
forward-looking statements. Readers of this press release are referred to
the Company's filings with the Securities and Exchange Commission,
including the Company's reports on Form 10-K and Forms 10-Q for further
discussions of factors that could affect the Company's business and its
future results. Forward-looking statements are based on the estimates and
opinions of management on the date the statements are made. The Company
assumes no obligation to update forward-looking statements if conditions or
management's estimates or opinions should change.
For more information about Bioject, visit http://www.bioject.com .
SOURCE Bioject Medical Technologies Inc.
 back to top
Related links:
http://www.bioject.com
CONTACT:
Jim O'Shea, Chief Executive Officer,
+1-503-692-8001 ext. 4161, or Chris Farrell, Vice President of
Finance, +1-503-692-8001 ext. 4132, both of Bioject Medical
Technologies Inc.
|
